MSD (Singapore)

MSD (Singapore) is described on its official site as the Singapore presence of a research-intensive biopharmaceutical company that aspires to deliver innovative health solutions for the prevention and treatment of diseases in people and animals. Its stated areas of focus include oncology, vaccines, infectious diseases, cardio-metabolic disorders and COVID-19. The company states it has brought hope to humanity through the development of important medicines and vaccines for more than 130 years, and that it has been discovering, developing and delivering vaccines to help prevent disease for over 100 years.

MSD (Singapore) presents itself as part of a research-intensive biopharmaceutical company that states it has brought hope to humanity through the development of important medicines and vaccines for more than 130 years, and that it has been discovering, developing and delivering vaccines to help prevent disease for over 100 years. Its Singapore site lists company statements including a June 18, 2025 announcement that MSD initiated a Phase 3 study evaluating a dengue vaccine candidate; a September 23, 2024 announcement that MSD received Singapore Health Sciences Authority (HSA) approval for WINREVAIR® (sotatercept) for the treatment of adults with pulmonary arterial hypertension (PAH); a February 9, 2023 announcement of MENDAKI's first corporate mentoring partnership with biopharmaceutical company MSD to mentor youth from ITE; an October 5, 2022 announcement that MSD launched new manufacturing facilities in Singapore for innovative medicines and vaccines; an April 20, 2022 announcement that MSD's COVID-19 oral antiviral LAGEVRIO® received interim authorization in Singapore; and an October 6, 2021 announcement that MSD announced a supply and purchase agreement with the Singapore Government for Molnupiravir.

Premier research-intensive biopharmaceutical company focused on scientific innovation to deliver medicines and vaccines.

• WINREVAIR® (sotatercept)

  Approved by the Singapore Health Sciences Authority (HSA) for the treatment of adults with pulmonary arterial hypertension (PAH).

• LAGEVRIO®

  MSD's COVID-19 oral antiviral that received interim authorization in Singapore.

• Molnupiravir

  Subject of a supply and purchase agreement between MSD and the Singapore Government.

1. 1MSD Singaporemsd-singapore.com
2. 2Company Overview - MSD Singaporemsd-singapore.com
3. 3Company statements - MSD Singaporemsd-singapore.com
4. 4MSD (Singapore)wikidata.org